23 May 2013
Keywords: centeon, begins, largest, worldwide, sepsis, study, planning
Article | 17 July 1997
Centeon is planning to conduct a 2,000-patient Phase III study to assessits antithrombin III product, Kybernin-P, as a treatment for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 September 1997
9 October 1997
22 May 2013
© 2013 thepharmaletter.com